Fox Run Management, L.L.C. Point Biopharma Global Inc. Transaction History

Fox Run Management, L.L.C.

  • $433 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$6.78 - $8.1 $140,644 - $168,026
20,744 New
20,744 $150,000

Others Institutions Holding PNT

# of Institutions
1
Shares Held
20K
Call Options Held
0
Put Options Held
0
View Full List

About POINT Biopharma Global Inc.

PNT Quotes by TradingView
  • Ticker PNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 104,025,000
  • Description
  • POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...
More about PNT
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email